Lymphoma News

A new voluntary oncology payment model the Biden administration announced earlier this summer has been met with support, as well as concerns, from several cancer organizations.

The FDA granted priority review to omidubicel, an investigational donor-based stem cell therapy for patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation.

Frailty assessments are important predictors of future health outcomes among geriatric patients with hematologic malignancies.

Perhaps no one has been better prepared to become a leader in the field of cancer cellular immunotherapy than Marcela V. Maus, MD, PhD.

Patients with early-stage classic Hodgkin lymphoma and other neoplasms exhibited higher risk for cardiovascular disease-associated mortality compared with cancer-associated mortality later in life, according to study results.

Age-adjusted incidence of anaplastic large-cell lymphoma of the breast rapidly increased in the U.S. between 2000 and 2018, according to a research letter published in JAMA Oncology.

Oncology clinical trials appeared to recover from declines in enrollment and activation during the early phase of the COVID-19 pandemic, according to a study of data from two large academic centers published in Annals of Oncology.

Researchers have developed a genetically modified form of the immune-stimulating protein interleukin-7 that significantly enhanced chimeric antigen receptor T-cell therapy activity in preclinical testing.

The FDA approved crizotinib for treatment of adults and children aged 1 year or older with anaplastic lymphoma kinase-positive unresectable, recurrent or refractory inflammatory myofibroblastic tumors.

Less than half of patients with hematologic malignances exhibited seroconversion after receiving their initial COVID-19 vaccine, research published in Cancer showed.